Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OliPass CTLA4 antisense oligonucleotide
- Development stage
- Preclinical
- Lead developer
- OliPass
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Topical, Oral, Intravenous, Intrathecal, Subcutaneous
01
Overview
OliPass CTLA4 antisense oligonucleotide is an investigational immuno-oncology therapeutic developed using a proprietary Peptide Nucleic Acid (PNA) platform. The drug is designed to target Cytotoxic T-lymphocyte-associated protein 4 (CTLA4), a well-characterized immune checkpoint that suppresses T-cell activity. Unlike conventional antisense oligonucleotides that rely on RNase H-mediated mRNA degradation, this PNA-based candidate utilizes an exon-skipping mechanism to modulate CTLA4 expression. By inhibiting the CTLA4 pathway, the drug aims to enhance the immune system's ability to recognize and destroy cancer cells. The program is currently in the research and preclinical development stage.
- Other names
- CTLA4-OliPassCTLA-4-OliPassCTLA 4-OliPassCTLA4 PNACTLA-4 PNACTLA 4 PNA
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)
Beyond the preview
Go deeper on OliPass CTLA4 antisense oligonucleotide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OliPass CTLA4 antisense oligonucleotide.